Eli Lilly, Novartis Could Pump Close To $3B Into AI Drug Tech
Eli Lilly & Co. and Novartis could invest close to $3 billion in the development of artificial intelligence for drug discovery under two new agreements with a digital biology company owned...To view the full article, register now.
Already a subscriber? Click here to view full article